Abstract: Disclosed are a matrix for restoring soft tissue and a method of producing the same, the method including: forming a sheet-type absorption layer (11) on one side of a double layer using biocompatible neutral collagen; forming a film-type support layer (12) on the remaining surface of the double layer by mixing collagen with a water-soluble polymer and a natural material; and forming a double layer-structured matrix (10) for restoring soft tissue by attaching the absorption layer (11) and the support layer (12) so as to treat damage to soft tissue of a mammal other than a human or restore damaged soft tissue. This invention pertains to the treatment of damage to soft tissue such as tendons, ligaments, and rotator cuffs or the restoration of damaged soft tissue, whereby the quality and reliability of products can be remarkably improved, thus satisfying various needs of consumers, who are the users thereof, and exhibiting a good effect.

Abstract: Disclosed are a matrix for restoring soft tissue and a method of producing the same, the method including: forming a sheet-type absorption layer (11) on one side of a double layer using biocompatible neutral collagen; forming a film-type support layer (12) on the remaining surface of the double layer by mixing collagen with a water-soluble polymer and a natural material; and forming a double layer-structured matrix (10) for restoring soft tissue by attaching the absorption layer (11) and the support layer (12) so as to treat damage to soft tissue of a mammal other than a human or restore damaged soft tissue. This invention pertains to the treatment of damage to soft tissue such as tendons, ligaments, and rotator cuffs or the restoration of damaged soft tissue, whereby the quality and reliability of products can be remarkably improved, thus satisfying various needs of consumers, who are the users thereof, and exhibiting a good effect.

Abstract: Disclosed are a biomaterial imparted with enhanced rubber properties through natural cross-linking between collagen and hyaluronic acid, a method of preparing the same, and a method of using the same, wherein the rubber-type biomaterial is prepared from collagen and hyaluronic acid at a ratio of 2:1 to 7:1 through natural cross-linking. Specifically, a novel material that exhibits rubber properties can be prepared from collagen and hyaluronic acid at an optimal mixing ratio taking into consideration the molecular structural properties thereof under natural cross-linking conditions, rather than chemical or physical cross-linkage, thereby remarkably improving the quality and reliability of products, ultimately fulfilling various needs of consumers to thus increase marketability.

Abstract: A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.

Abstract: Cell manipulation and cultivation equipment for the production of cell therapy products has developed for preventing contamination of cells and improving the utility of a space. The equipment includes a room for the production and testing of cell therapy products, the room having an inner space enclosed in all sides and an outer entrance/exit door provided at any one side thereof, an L-shaped partition installed in a position of the room for the production and testing of cell therapy products, the partition having an inner entrance/exit door provided at any one side thereof, and a clean bench device placed inside the partition, the clean bench device including first, second, and third clean benches for preventing contamination of cells and increasing the utility of a space to the maximum extent. The operating of the clean room and clean bench has advantages to prevent contamination and improving the quality and reliability of cell therapy products.

Abstract: A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix to prepare an osteoblast therapeutic agent. A bone formation method is provided that results in no clinical graft rejection, and is capable of achieving effective and rapid bone formation via injection of a compound which has been pre-shaped to a certain extent, so as to alleviate problems associated with bone tissue formation in unwanted regions resulting from escape of injected osteoblasts from the targeted site for bone formation and then propagation thereof to other sites via the blood stream, which are caused by injection of an osteoblast suspension.

Abstract: A method of transplanting an injectable chondrocyte is developed for autologous chondrocyte transplantation, comprising mixing matrices including fibrin, hyaluronic acid and collagen, which are the main ingredients of animal cartilage, and injecting the resulting mixture into a damaged cartilage region. One 1 ml syringe is prepared by mixing 1 ml of a chondrocyte culture with white or light-yellow lyophilized powder (fibrinogen). A second 1 ml syringe is prepared by mixing 1 ml of chondrocyte culture with white lyophilized powder (thrombin), adding 0.1 cc of that mixture to the entire contents of two vials containing chondrocyte suspension, and mixing well. The two syringes are then mounted on a syringe stand, and a mixing tip is mounted to their tips. The contents are mixed in the mixing tip while injecting the resulting mixture into a damaged cartilage region of an animal.

Abstract: A facility module is provided for producing and storing a cell therapy product comprising: a Cell Therapy (CT) module one including separately prefabricated units having specific functions and separate entrances and exits so as to minimize contamination, and being capable of producing the cell therapy product, and a Banking of Cell and Tissue (BC) module Two including prefabricated units having specific functions and separate entrances and exits so as to minimize contamination, and being capable of appropriately storing hematopoietic stem cells, bone marrow cells and other cells for a prolonged period. It enables easy and low cost production of the cell therapy product, with sufficient quality to be transplanted into patients, within a short period, and permits clinical application to patients expeditiously.

Abstract: A method is provided for utilizing a cell therapy product facility and an internet franchise market business comprising: producing a cell therapy product by a CT (Cell Therapy)-module (1) of prefabricated units having specific functions, and; storing of hematopoietic stem cells, bone marrow cells and other cells, by a BC (Banking of Cell and Tissue)-module (2) of prefabricated units having specific functions. Both modules eliminate contamination and maximize efficiency. It provides an operating method and a use method and business method for the above cell therapy product facility. The invention enables easy, low cost production of a product having sufficient quality to be transplanted into patients and put into clinical application within a short period of time. The facility module of the invention can be installed and used wherever adequate space is available. The invention provides improved quality and reliability of cell therapy products.

Abstract: A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (?-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area.

Abstract: A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.

Abstract: A cartilage therapeutic composition is developed for clinical transplantation into articulatio genu (knee joints) or ankle joints. It has clinical significance for symptomatic cartilage defects of the femoral condyle (medial, lateral, or trochlear) and bone cartilage defects of the talus (anklebone) in human or animal hosts, The cartilage therapeutic composition comprises a mixture of components of chondrocytes isolated and expanded or differentiated from a host such as a human or animal, and thrombin and a fibrinogen matrix containing fibrinogen. An application of the cartilage therapeutic composition is that a mixture of thrombin, chondrocyte components and a fibrinogen matrix is injected into a cartilage defect region followed by solidification therein. It provides rapid healing and effective regeneration of cartilage without surgical operation. It has the merits of safety and simplicity by allowing the use of an arthroscope for transplantation.